Positive final results from the Phase III COSMIC-311 trial for Cabometyx (cabozantinib) were reported by Exelixis for patients diagnosed with previously treated radioactive iodine-refractory differentiated thyroid cancer.
https://www.pharmalive.com/wp-content/uploads/2021/09/Cabometyx-Proves-its-Worth-in-Phase-III-Differentiated-Thyroid-Cancer-Study-BioSpace-9-21-21.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2021-09-21 12:03:482021-09-21 13:17:46Cabometyx Succeeds in Phase III Study for Differentiated Thyroid Cancer